
usd jan pm et
summari diversifi health care product compani focus nutrit product
diagnost gener drug medic devic
price-to-earnings oper ep
strong posit key health care product
categori robust product pipelin
compani recent paid signific amount
acquisition-rel debt also histori robust
free cash flow gener given compani financi
stabil commit invest expans
product portfolio think low oper
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan pm stock trade
expect sale increas
abt
sale growth continu led
medic devic diagnost
busi organ basi expect
devic sale grow low-doubl digit
diagnost mid- high-singl digit
pharmaceut mid- high-singl digit
nutrit low- mid-singl digit
long-term growth driver well
posit benefit rapid growth
health care spend market
market made abt
revenu expect abt foreign
exchang exposur neg impact
sale signific
improv headwind
expect adjust gross margin
remain flat yoy spite underli
margin expans invest
support rapid adopt alin diagnost
system expand
manufactur capac freestyl libr
continu glucos monitor mitraclip
think share trade
forward earn upsid potenti due
sustain earn growth opportun
driven plethora innov
recent upcom offer across
compani divis addit size
organ like allow better
endur econom slowdown
price pressur come recent
consolid health care player
particularli hospit favor
long-term view exposur
high-growth therapeut area
diseas diagnost
risk target price recommend
opportun weak execut new key
unfavor currenc movement
target base
above-p ep
estim continu
expect achiev above-market organ
sale growth robust earn growth
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
chairman board
execut vice-president financ
corpor overview oper four report segment establish
pharmaceut product brand gener diagnost product nutrit product well
cardiovascular neuromodul product combin segment gener billion sale
dec come establish pharmaceut diagnost
nutrit medic devic primarili compris cardiovascular
neuromodul product divers oper larg result strateg acquisit made
year well intern research develop program abbott command
lead market posit mani product sell
establish pharmaceut segment product includ broad line brand gener
pharmaceut manufactur world-wide market sold outsid unit state emerg
market product gener sold directli wholesal distributor govern agenc
health care facil pharmaci independ retail abbott-own distribut center
public warehous depend market serv growth strategi busi
increas breadth product offer launch new improv formul regist
product across multipl geograph region competit segment gener health
care pharmaceut compani
diagnost product includ broad line diagnost system test manufactur market
sold world-wide princip product segment includ molecular diagnost system point care
system rapid diagnost system informat autom solut use laboratori core
laboratori system area immunoassay clinic chemistri hematolog transfus
next-gener famili core laboratori system brand alin product segment
subject competit technolog innov price conveni use servic instrument warranti
provis product perform laboratori effici long-term suppli contract product potenti
overal cost-effect product gain
nutrit product includ broad line pediatr adult nutrit product manufactur
market sold world-wide product includ variou form prepar infant formula
similac adult pediatr nutrit product ensur nutrit product use enter
feed jeviti nutrit brand zone perfect bar competit factor
price retail distribut avail product form signific aspect competit search
ingredi innov
cardiovascular neuromodul product includ broad line rhythm manag
electrophysiolog heart failur vascular structur heart devic treatment cardiovascular
diseas well neuromodul devic manag chronic pain movement
disord product segment subject competit technolog innov price
conveni use servic product perform long-term suppli contract product potenti
overal cost-effect product gain
also product blood glucos continu glucos monitor system
includ freestyl brand
impact major develop make major acquisit make sens
complet two major acquisit also anticip make major
acquisit believ compani plenti organ growth opportun invest
two major acquisit aler lead firm point-of-car diagnost octob
billion cash st jude medic stj leader cardiac neuromodul
devic januari billion total believ combin stj enabl
becom leader cardiovascular care
also complet sale abbott medic optic vision care busi johnson
johnson billion februari complet sale non-u develop market
specialti brand gener busi mylan nv billion
financi trend revenu grew year-over-year billion dec
compar oper basi sale increas acceler achiev
spent billion revenu research develop compar
billion revenu billion revenu normal ep
growth acceler trailing-twelv month free cash flow
determin cash flow oper less capit expenditur billion june
billion year ago june manag moder level debt
net debt capit net debt trailing-twelve-month ebitda
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc novemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neutral expect
compani continu achiev robust organ
growth mid- high-single-digit revenu
growth driven new product
data provid estim world-wide medic
devic sale grow
time think potenti slowdown
macroeconom growth could pressur
industri driver yet sub-industri
includ mani product area
histor recession-resist
equip use non-elect procedur
gener see posit long-term
fundament medic devic manufactur
includ increas global demand
popul rise outlay
result steadi flow innov product
revenu growth
polit regulatori perspect
medic devic industri larg avoid
scrutini unlik area health
drug maker fact medic devic tax
final repeal decemb remov
signific risk sale devic maker
think industri continu
dwindl industri come back
favor especi sinc valuat health
rel
forward price-to-earn basi think
higher valuat sub-industri
mostli warrant margin expans
revenu growth opportun associ
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much
commentari around introduct mdr
reason believ new
regul could neg impact
industri exampl juli
submit letter world trade
organ request mdr ivdr
delay three year also novemb
associ critic slow piecem
implement new regulatori
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
expect industri earn rise
low-double-digit percentag driven sale
new product command higher
margin project industri oper
ebit margin
estim margin
 health equip
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
vs equal estim maintain ep estim
ep sale increas organ billion
organ basi sale grew nutrit busi
diagnost establish pharmaceut medic devic
strength medic devic busi driven double-digit growth
electrophysiolog heart failur structur heart diabet care
neuromodul part medic devic segment underperform
reflect declin organ sale expect see turnaround
busi recent salesforc expans becom less disrupt
et cfra maintain buy opinion share
rais target price reflect
above-p multipl ep estim
continu expect exposur high-growth therapeut area drive
above-market organ sale double-digit earn growth ep
vs lower estim lower ep estim
initi ep sale increas
organ billion organ basi sale grew
nutrit busi diagnost establish
pharmaceut medic devic manag
current see compel opportun especi sinc
plenti organ growth opportun manag also note growth
expect depend key approv mitraclip freestyl
libr product see potenti share upsid /kevin huang
analyst research note compani news
pm et cfra maintain buy opinion share
rais target price reflect
above-p multipl ep estim trade
peer firm success execut long-term plan
deliv low double-digit ep growth new recent product ep
vs equal consensu estim keep ep
estim initi ep estim sale
grew billion slightli expect organ basi
sale grew led growth medic devic follow
establish pharmaceut diagnost nutrit
segment demonstr acceler yoy growth sale abt
mitraclip grew organ million expect
structur heart group sale continu driven mitraclip aid
european launch triclip tricuspid valv repair tendyn mitral
et cfra reiter buy opinion share
maintain target reflect above-p
multipl ep estim despit
compani matur see opportun ep growth acceler
sustain top-line growth margin expans ep vs fell
short estim lower ep estim
keep ep sale grew billion
reflect organ growth sale grew organ
nutrit busi diagnost establish
pharmaceut medic devic see posit potenti
recent work toward integr glucos sens technolog
insulin deliveri technolog partner sanofi omada health
manag comment spite trade
tension econom concern busi perform well
china issu relat said concern /kevin huang cfa
pm et cfra maintain buy opinion share
lift target reflect above-p
multipl ep estim rais
ep estim ep despit
compani matur see opportun ep growth acceler
ep vs equal estim sale grew
billion reflect acceler organ growth organ
basi sale grew nutrit busi diagnost
establish pharmaceut medic devic impress
quarter growth sale freestyl libr continu
glucos monitor system world-wide sale increas organ
million soon increas manufactur capac address
overwhelm demand libr structur heart sale mitraclip
devic grew world-wide led growth
pm et cfra maintain buy opinion share
increas price target reflect forward price-to-earnings
multipl next-twelve-month ep estim multipl
compani three-year forward price-to-earnings rang
expect achiev acceler ep growth rise exposur
promis high-growth therapeut area despit one largest
well-establish medic devic manufactur grow ep
compound annual growth rate compound-annual-growth-rate three year end
estim compani three-year compound-annual-growth-rate end
/kevin huang cfa
et cfra reiter buy opinion share
rais price target reflect
above-p multipl ep estim
exposur high-growth therapeut area opinion drive
above-market organ sale double-digit earn growth ep
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
